Torna all'elenco degli studi

A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

CODICE STUDIO

NCT06183489

TIPOLOGIA

SMM

NOME SPONSOR

European Myeloma Network

DESCRIZIONE

Trattamento

Participant Group/Arm
Experimental: Elranatamab

Participant will receive Elranatamab subcutaneously (SC) for 24 cycles (28-day cycle)

 

Intervention/Treatment
Drug: Elranatamab

  • Elranatamab will be administered via a subcutaneous injection (SC)
Leggi tutto

FARMACI UTILIZZATI

Elranatamab